


# CANCER GENOMICS & PROTEOMICS

Volume 21, Number 2, March-April 2024

ISSN (online): 1790-6245



Published by the International Institute of Anticancer Research

# CANCER GENOMICS & PROTEOMICS

Online ISSN: 1790-6245

## Editor-in-Chief:

**ARUN SETH**, *Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada*

## Managing Editor:

**G.J. DELINASIOS**, *International Institute of Anticancer Research (IIAR), Kapandriti, Attiki, Greece*

## Managing Editor (2004-2016):

**J.G. DELINASIOS**, *International Institute of Anticancer Research (IIAR), Kapandriti, Attiki, Greece*

## Editorial Board

**L. A. Aaltonen**, *Helsinki, Finland*

**R. Abagyan**, *La Jolla, CA, USA*

**D.-T. Bau**, *Taichung, Taiwan, ROC*

**R. Clarke**, *Washington, DC, USA*

**A. M. Dubuc**, *Boston, MA, USA*

**T. Efferth**, *Mainz, Germany*

**N. A. Ellis**, *Tucson, AZ, USA*

**A. Facoetti**, *Pavia, Italy*

**C.V. Forst**, *New York, NY, USA*

**G. Glinsky**, *San Diego, CA, USA*

**T.R. Golub**, *Cambridge, MA, USA*

**J. Gordon**, *Philadelphia, PA, USA*

**C.-H. Heldin**, *Uppsala, Sweden*

**J. D. Hoheisel**, *Heidelberg, Germany*

**T. H. M. Huang**, *San Antonio, TX, USA*

**S. C. Jhanwar**, *New York, NY, USA*

**J. Ju**, *Stony Brook, NY, USA*

**O. P. Kallioniemi**, *Turku, Finland*

**K. Khalili**, *Philadelphia, PA, USA*

**D. G. Kieback**, *Schleswig, Germany*

**S. D. Kottaridis**, *Athens, Greece*

**Y. T. Kwon**, *Seoul, Republic of Korea*

**B. Léyland-Jones**, *Rockville, MD, USA*

**P. Lichter**, *Heidelberg, Germany*

**A. Lindblom**, *Stockholm, Sweden*

**G. Lubec**, *Vienna, Austria*

**P. J. McCormick**, *Rensselaer, NY, USA*

**F. Mitelman**, *Lund, Sweden*

**C. Nicot**, *Kansas City, KS, USA*

**L. O'Driscoll**, *Dublin, Ireland*

**C. D. Platsoucas**, *Norfolk, VA, USA*

**J. Quackenbush**, *Boston, MA, USA*

**J. S. Rader**, *Milwaukee, WI, USA*

**R. H. Reeves**, *Baltimore, MD, USA*

**T. Ried**, *Bethesda, MD, USA*

**G. Rimbach**, *Kiel, Germany*

**K. D. Rodland**, *Richland, WA, USA*

**C. Sansom**, *London, UK*

**N. A. Saunders**, *Queensland, Australia*

**B.W. Schäfer**, *Zurich, Switzerland*

**J. Schneider**, *Valladolid, Spain*

**O. J. Semmes**, *Norfolk, VA, USA*

**G. V. Sherbet**, *Newcastle-upon-Tyne, UK*

**S. Smith**, *Duarte, CA, USA*

**J. C. Strefford**, *Southampton, UK*

**G. Tsangaris**, *Athens, Greece*

**U.H. Weidle**, *Penzberg, Germany*

**H. Zhang**, *New Haven, CT, USA*

## Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd.,

P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: [journals@iilar-anticancer.org](mailto:journals@iilar-anticancer.org) (Editorial Office)

[editor@iilar-anticancer.org](mailto:editor@iilar-anticancer.org) (Managing Editor)

[www.iilar-anticancer.org](http://www.iilar-anticancer.org)

<http://cgp.iiarjournals.org>

Front cover photograph: Figure 1A-D, page 147.

**Editorial Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The Journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-2 months from acceptance.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences, please visit the IIAR website: [www.iilar-anticancer.org](http://www.iilar-anticancer.org)

**Publication Data:** CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises of six issues. CANCER GENOMICS & PROTEOMICS Vol. 1 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

**Open Access Policy:** CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of US\$ 950.00 (effective January 1, 2023) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged US\$ 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

**Copyright:** Authors retain copyright. The unrestricted *non-commercial* use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in CGP are the property of the publisher.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [editor@iilar-anticancer.org](mailto:editor@iilar-anticancer.org)

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, University of Toronto, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737. E-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

The Editors and Publishers of CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

# CANCER GENOMICS & PROTEOMICS

Print ISSN (2004-2012): 1109-6535  
Online ISSN: 1790-6245

VOLUME 21, No 2  
2024

## Editorial Board

|                         |  |
|-------------------------|--|
| <b>A. Seth</b>          | Editor-in-Chief<br>Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada |
| <b>G.J. Delinasios</b>  | Managing Editor and Executive Publisher<br>International Institute of Anticancer Research, Athens, Greece  |
| <b>L.A. Aaltonen</b>    | Department of Medical Genetics, University of Helsinki, Helsinki, Finland  |
| <b>R. Abagyan</b>       | The Scripps Research Institute, La Jolla, CA, USA  |
| <b>D.-T. Bau</b>        | Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC  |
| <b>R. Clarke</b>        | Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA   |
| <b>A.M. Dubuc</b>       | Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA  |
| <b>T. Efferth</b>       | Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany   |
| <b>N.A. Ellis</b>       | Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA  |
| <b>A. Facoetti</b>      | Fondazione CNAO, Pavia, Italy  |
| <b>C.V. Forst</b>       | Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA                     |
| <b>G. Glinsky</b>       | Institute of Engineering in Medicine, University of California, San Diego, CA, USA   |
| <b>T.R. Golub</b>       | Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA   |
| <b>J. Gordon</b>        | Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA  |
| <b>C.-H. Heldin</b>     | Ludwig Institute for Cancer Research, Uppsala, Sweden  |
| <b>J.D. Hoheisel</b>    | Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany  |
| <b>T.H.M. Huang</b>     | Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA                                |
| <b>S.C. Jhanwar</b>     | Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA   |
| <b>J. Ju</b>            | Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA  |
| <b>O.P. Kallioniemi</b> | Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland  |
| <b>K. Khalili</b>       | College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA   |
| <b>D.G. Kieback</b>     | Helios Medical Center Schleswig, Schleswig, Germany  |
| <b>S.D. Kottaridis</b>  | Department of Virology, Hellenic Anticancer Institute, Athens, Greece  |
| <b>Y. T. Kwon</b>       | Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea  |
| <b>B. Léyland-Jones</b> | National Foundation for Cancer Research (NFCR), Rockville, MD, USA   |
| <b>P. Lichter</b>       | Deutsches Krebsforschungszentrum, Heidelberg, Germany  |
| <b>A. Lindblom</b>      | Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden   |
| <b>G. Lubec</b>         | Department of Pediatrics, University of Vienna, Austria  |
| <b>P.J. McCormick</b>   | The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA                                   |
| <b>F. Mitelman</b>      | Department of Clinical Genetics, University Hospital, Lund, Sweden   |
| <b>C. Nicot</b>         | Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA   |
| <b>L. O'Driscoll</b>    | School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland   |
| <b>C.D. Platsoucas</b>  | College of Sciences, Old Dominion University, Norfolk, VA, USA   |
| <b>J. Quackenbush</b>   | Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA   |
| <b>J.S. Rader</b>       | Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA  |
| <b>R.H. Reeves</b>      | Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA   |
| <b>T. Ried</b>          | Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA   |
| <b>G. Rimbach</b>       | Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany  |

|                       |   |
|-----------------------|---|
| <b>K.D. Rodland</b>   | Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA                                |
| <b>C. Sansom</b>      | The School of Crystallography, Birkbeck College, University of London, London, UK                                     |
| <b>N.A. Saunders</b>  | Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia |
| <b>B.W. Schäfer</b>   | Department of Oncology, University Children's Hospital, Zurich, Switzerland   |
| <b>J. Schneider</b>   | Universidad de Valladolid, Valladolid, Spain  |
| <b>O.J. Semmes</b>    | Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA              |
| <b>G.V. Sherbet</b>   | University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK     |
| <b>S. Smith</b>       | City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA                                     |
| <b>J.C. Strefford</b> | Cancer Science Division, Southampton General Hospital, Southampton, UK  |
| <b>G. Tsangaridis</b> | Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece       |
| <b>U.H. Weidle</b>    | Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany                         |
| <b>H. Zhang</b>       | Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA                  |

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services:

PubMed, PubMed Central, MEDLINE, CAS (Chemical Abstracts Service); Biological Abstracts; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS Previews; Science Citation Index Expanded (Web of Science); Essential Science Indicators; Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org).

**Editorial Office in U.S.A.:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Managing Editor: [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org).

Web: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org).

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org)

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

# CANCER GENOMICS & PROTEOMICS

**Volume 21, Number 2, March-April 2024**

*Review*

- CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia. A. NOPORA, U.H. WEIDLE (*Penzberg, Germany*) .....

118

*Articles*

- Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma. Y. OKUDA, T. KATO, K. FUJITA, H. FUSHIMI, H. MIYAMOTO, G.J. NETTO, N. NONOMURA (*Suita; Sayama, Osaka, Japan; Rochester, NY; Birmingham, AL, USA*) .....

137

- Non-homologous End-joining Genotype, mRNA Expression, and DNA Repair Capacity in Childhood Acute Lymphocytic Leukemia. C-C. CHEN, W-S. CHANG, J-S. PEI, C-C. KUO, C-H. WANG, Y-C. WANG, P-C. HSU, J-L. HE, J. GU, D-T. BAU, C-W. TSAI (*Taoyuan; Taichung, Taiwan, ROC; Houston, TX, USA*) .....

144

- POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma. D. SHIMIZU, M. ISHIBASHI, T. YAMADA, Y. TODA, S. HOSOGI, E. ASHIHARA (*Kyoto, Japan*) .....

158

- CUL4A Ubiquitin Ligase Is an Independent Predictor of Overall Survival in Pancreatic Adenocarcinoma. P. TAVLAS, S. NIKOU, C. GERAMOUTSOU, P. BOSGANA, S.C. TSANIRAS, M. MELACHRINOU, I. MAROULIS, V. BRAVOU (*Patras; Kapandriti, Greece; Cold Spring Harbor, NY, USA*) .....

166

- Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models. H. KINOSHITA, S. KINOSHITA, H. KAMODA, Y. HAGIWARA, S. OHTORI, T. YONEMOTO (*Chiba, Japan*) .....

178

- PRIM2: A Marker of MYC-driven Hyper-proliferation, Disease Progression, Tumor Aggressiveness and Poor Survival in Glioma Patients. R. SUN, X. SHAO, F. AKTER, K.R. ZAHID, S. YAO, L. MA, G. XU (*Guangzhou; Wuhan, PR China; Cambridge, MA; Birmingham, AL, USA*) .....

186

- Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer. K. MIZUTANI, S. SUGIYAMA, K. KAMEYAMA, S. KAMEI, S. YOKOI, A. MORIKAWA, M. TAKEUCHI, K. SEIKE, T. YAMADA, H. EHARA, S. SAWADA, K. HIRADE, H. FURUTA, K. MATSUNAGA, T. YAMADA, I. SAKAMOTO, Y. KATO, H. NISHIHARA, S. ISHIHARA, T. DEGUCHI (*Minokamo; Seki; Kakamigahara; Gifu; Hamamatsu-cho; Shinjuku, Japan*) .....

203